Biodel Inc. (NASDAQ:BIOD) on 24 April announced that it has signed a research supply and technology development agreement with HEC Pharm for ultra-rapid-acting insulin aspart. Insulin aspart is the active pharmaceutical ingredient (API) in Novo Nordisk ‘s ( NVO ) Novolog. Biodel Inc. (NASDAQ:BIOD) will issue its second quarter fiscal year 2014 financial results on May 13, 2014. Biodel Inc. (NASDAQ:BIOD) weekly performance is -0.43%. On last trading day company shares ended up $2.32. Analysts mean target price for the company is $6.00. Biodel Inc. (NASDAQ:BIOD) distance from 50-day simple moving average (SMA50) is -15.85%.
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) on 5 may reported financial results for the quarter ended March 31, 2014. The net loss for the first quarter was $10.7 million compared to $20.7 million during the same quarter in 2013. At March 31, 2014, Alexza had consolidated cash, cash equivalents, marketable securities and restricted cash of $60.0 million. Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) shares advanced 0.72% in last trading session and ended the day on $4.21. ALXA return on assets is -85.30%.Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) quarterly performance is -17.45%.
Zogenix (NASDAQ:ZGNX)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a report issued on Monday, American Banking News reports. They currently have a $5.00 price target on the stock, down from their previous price target of $6.00. William Blair’s price target would suggest a potential upside of 120.26% from the stock’s previous close. Zogenix, Inc. (NASDAQ:ZGNX) shares moved down -0.87% in last trading session and was closed at $2.27, while trading in range of $2.26 – $2.34. Zogenix, Inc. (NASDAQ:ZGNX) year to date (YTD) performance is -34.01%.
On April 23, 2014, Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) issued a press release announcing that is has begun the process required to establish an expanded access program to make available in the United States its investigational potassium channel inhibitor, Firdapse, to patients diagnosed with Lambert-Eaton Myasthenic Syndrome through their neuromuscular disease specialists. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) ended the last trading day at $1.82. Company weekly volatility is calculated as 6.05% and price to cash ratio as 5.16.Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) showed a negative weekly performance of -9.45%.
Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) Net loss for the quarter ended March 31, 2014 was approximately $2.8 million, or $0.15 per share (basic and diluted), compared to net loss of approximately $10.5 million, or $0.56 per share (basic and diluted), for the quarter ended March 31, 2013. Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) weekly performance is -0.68%. On last trading day company shares ended up $2.94. Analysts mean target price for the company is $4.10. Transcept Pharmaceuticals Inc. (NASDAQ:TSPT) distance from 50-day simple moving average (SMA50) is -3.83%.